Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS
Study data from M.D. Bobardt and co-authors update knowledge of HIV/AIDS
July 9th, 2008
According to a study from the United States, "In the absence of an effective vaccine, there is an urgent need for safe and effective antiviral agents to prevent transmission of HIV." "Here, we report that an amphipathic a-helical peptide derived from the hepatitis C virus NS5A anchor domain (designated C5A in this article) that has been shown to be virocidal for the hepatitis C virus (HCV) also has potent antiviral activity against HIV. C5A exhibits a broad range of antiviral activity against HIV isolates, and it prevents infection of the three in vivo targets of HIV: CD4(+) T lymphocytes, macrophages, and dendritic cells by disrupting the integrity of the viral...
Source: Vaccine Weekly (2008-07-09)
|
